Brief: Acurx Pharmaceuticals-Filed Protocol Amendment To Ind With FDA To Allow For Idmc To Review Interim Clinical Data From Ongoing Phase 2B Clinical Trial
16/03/2023 11:35
March 16 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX PHARMACEUTICALS-FILED PROTOCOL AMENDMENT TO IND WITH
FDA
TO ALLOW FOR IDMC TO REVIEW INTERIM CLINICAL DATA FROM ONGOING
PHASE 2B CLINICAL TRIAL
* ACURX PHARMACEUTICALS INC - IF ACCEPTABLE TO FDA, IDMC
WILL
REVIEW CLINICAL DATA UPON ENROLLMENT OF 36 PATIENTS IN PHASE 2B
CLINICAL TRIAL
* ACURX PHARMACEUTICALS INC - CURRENTLY HAS ENROLLED 25
PATIENTS
IN PHASE 2B CLINICAL TRIAL
* ACURX PHARMACEUTICALS INC - IDMC WILL DETERMINE, RECOMMEND
WHETHER TO EARLY TERMINATE PHASE 2B CLINICAL TRIAL OR TO
CONTINUE PATIENT ENROLLMENT
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln